*Packaging may vary based on availability.
Generic for Protopic · Non-steroidal ointment · 30g
Tacrolimus 0.03% ointment is FDA-approved for atopic dermatitis in patients aged 2 to 15 — the only non-steroidal prescription topical indicated specifically for the pediatric age group. It addresses the most persistent challenge in childhood eczema: the face.
Facial eczema is both the most visible and the most emotionally difficult aspect of eczema in children, and it’s where topical steroids present the hardest trade-off — effective short term, but not appropriate for continuous long-term use because of atrophy risk in growing skin. Tacrolimus doesn’t bind glucocorticoid receptors and doesn’t affect collagen or elastin synthesis, so it can be part of long-term disease control without structural cost. The 0.03% strength is the FDA-approved pediatric dose; 0.1% is not approved for children under 16.
Tacrolimus inhibits calcineurin, an enzyme T-cells need to activate NFAT — the transcription factor T-cells need to produce inflammatory cytokines including IL-2, IL-4, IL-5, and IFN-γ. Without NFAT, the T-cell–driven cascade sustaining eczema cannot amplify. The skin retains normal immune function — it can still respond to infections — but the hyperreactive response that constitutes eczema is suppressed at its source.
Because tacrolimus is entirely independent of the glucocorticoid receptor pathway, it has no effect on collagen, elastin, or HPA-axis cortisol production. Treated skin looks and behaves structurally the same after months or years of use. Transient burning or stinging in the first days of use is a direct effect on skin nerve fibers (TRPV1 activation) — not a sign of damage — and typically resolves within 3–5 days as those receptors desensitize.
Tacrolimus 0.03% ointment received FDA pediatric approval following dedicated phase III RCTs in children aged 2–15. Pivotal trials demonstrated significantly greater reduction in EASI scores versus vehicle, comparable efficacy to mild-to-moderate potency topical steroids for facial eczema, and — crucially — no skin atrophy on histological examination with up to 12 months of use.
Long-term safety studies specifically in children confirm no cumulative skin structural changes, no HPA-axis suppression, and no growth effects with 0.03% over periods of a year or more. This is the longitudinal data that supports its role as a genuine long-term management tool.
Application-site burning and stinging is the main side effect in children, and often more challenging to manage because a child who experiences discomfort is less likely to cooperate. This is a direct pharmacological effect that resolves within 3–5 days as skin nerve fibers desensitize. Preparing the child and parent for this in advance — framing it as temporary and expected — dramatically improves continuation. Some families apply at night after the child is asleep.
Tacrolimus carries an FDA boxed warning about a theoretical risk of lymphoma and skin cancer with long-term use. The theoretical concern came from animal studies at doses far exceeding topical application and from organ-transplant patients on systemic (oral) tacrolimus. Large post-marketing studies following children who used topical tacrolimus have not found any increased rate of lymphoma or skin cancer. Not appropriate for infected skin — eczema herpeticum (herpes simplex spreading across eczematous skin) is a contraindication. Disclose any history of cold sores or recurrent HSV to your clinician.
| Traditional | With Fern | |
|---|---|---|
| Doctor appointment | ~30 days to book | 5-hour clinician review |
| Getting the Rx | Separate pharmacy trip | Shipped to your door |
| Cost | Insurance + copays | $35/mo, no insurance |
| Follow-up | Second appointment | Message the care team |
Don’t stop, but do try the application strategies that reduce the initial stinging. Apply to cooler skin (not immediately after a warm bath). Apply at bedtime when the child may be drowsier. Use the smallest effective amount. The stinging diminishes rapidly — most children who make it through the first 3–5 days find subsequent applications much less uncomfortable. It isn’t harmful; it’s TRPV1 receptor activation, and those receptors desensitize.
You should know about it and ask your clinician about it. The honest summary: the FDA boxed warning was required based on theoretical mechanistic concern and animal data, and it has not been confirmed by post-marketing studies tracking children who actually used topical tacrolimus. Registry analyses have not found elevated cancer incidence. The AAD has published position statements noting the evidence does not support a meaningful cancer risk from topical use.
Yes — FDA approval starts at age 2. Below age 2, the prescribing information does not include tacrolimus 0.03%, and most clinicians stick within the approved age range for a medication with a boxed warning. For children under 2 with significant eczema, low-potency steroids are the current standard while they reach the approved age for calcineurin inhibitor use.
Twice daily for active flares; once daily or twice weekly for maintenance once the skin has cleared. The proactive twice-weekly approach on historically affected skin has solid evidence and is used in children for chronic facial involvement. Your clinician will specify the schedule based on your child’s pattern.
Many children’s eczema severity decreases as they age, particularly those who develop it in infancy or early toddlerhood. Tacrolimus is a tool for the period when active management is needed; it doesn’t alter the underlying disease course. If your child has been well-controlled for 6–12 months, you can try tapering to see if the disease activity warrants continued treatment.
Fern clinicians review every case individually. Most patients hear back in under 3 hours.
Start your child's assessment →This information is for educational purposes only and is not medical advice. Consult with a healthcare provider before starting any treatment.
“There’s a specific look I recognize in eczema patients who’ve been managing on their own too long. They’ve stopped believing it can get better. Fern shortens that window of suffering. It gets people into real treatment before hopelessness sets in.”